Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614115 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
A Phase 1 study of End-Stage Kidney Disease and Kidney Failure, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT05614115: Completed Phase 1 study of End-Stage Kidney Disease and Kidney Failure, sponsored by University of Utah.
NCT05614115 is a Phase 1 study of End-Stage Kidney Disease and Kidney Failure that has completed, run by University of Utah. The registered enrollment target is 62 participants, below the 463-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614115, a Phase 1 study of End-Stage Kidney Disease and Kidney Failure, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and non-diabetic patients. Although patients with severe chronic kidney disease and ESKD have very high risk of heart failure and cardiovascular death, they have been excluded from all of the previous studies. If this medication is found to be well tolerated and safe in dialysis patients through this study, future clinical studies can evaluate if this medication can also reduce the risk of heart failure and cardiovascular death in dialysis patients.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Empagliflozin
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
What the finished NCT05614115 record still lists
NCT05614115 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 463-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (87% lower).
The record links to 8 conditions, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05614115 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05614115 about?
NCT05614115 is a clinical study titled "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD". The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent heart failure hospita...
What is the current status of trial NCT05614115?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2023-03-21. Estimated completion is 2025-06-30.
What conditions does trial NCT05614115 study?
This clinical trial studies the following conditions: End-Stage Kidney Disease, Kidney Failure, Hemodialysis, Kidney Disease, Chronic, Dialysis.
What interventions are being tested in trial NCT05614115?
The interventions under investigation include: Placebo (OTHER), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT05614115?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614115 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End-Stage Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05614115's enrollment target sits among peer trials
62 12th of 20 higher than 9 of 20 other End-Stage Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End-Stage Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
RECRUITING · Phase 1
-
Immunological Tolerance in Patients With Mismatched Kidney Transplants
ACTIVE NOT RECRUITING · Phase 1
-
Incremental Hemodialysis: The TwoPlus Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI